Levetiracetam Viatris (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, modulating neurotransmitter release and reducing excessive neuronal firing. This stabilizes neuronal networks and helps prevent the spread of seizure activity without directly affecting ion channels or GABA receptors.

The dosage of Levetiracetam Viatris is individualized by the prescribing clinician based on the patient’s age, renal function, seizure type, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Levetiracetam is classified as Pregnancy Category B, indicating no evidence of fetal risk in animal studies but a lack of well‑controlled human data. It may be used during pregnancy if the potential benefit justifies the risk. Small amounts are excreted in breast milk; breastfeeding mothers should discuss risks and benefits with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Levetiracetam offers a favorable safety profile with minimal enzyme‑inducing properties, reducing the likelihood of drug‑drug interactions compared with many older antiepileptics such as carbamazepine or phenytoin. Its unique SV2A binding mechanism provides effective seizure control, especially in patients who have not responded to other therapies.

Levetiracetam Viatris tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Levetiracetam Viatris is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with water and not chewed or crushed unless specifically instructed.

Serious risks include severe allergic reactions (e.g., rash, swelling, breathing difficulty), mood disturbances such as depression or suicidal thoughts, and rare hematologic abnormalities. Patients should seek immediate medical attention if they experience any of these symptoms.

Levetiracetam is contraindicated in patients with known hypersensitivity to levetiracetam or any of its excipients. Caution is advised for individuals with severe renal impairment, uncontrolled psychiatric conditions, or those taking interacting medications that may significantly alter its efficacy.